Herold II ITN007AI: Treatment with hOKT3-gamma-1 (Ala-Ala) in Type 1 Diabetes Mellitus

Kevan Herold
This is a phase II study examining clinical and immunological effects of humanized FcR non-binding anti-CD3 mAb in participants with Type 1 diabetes mellitus (T1DM), and to develop this therapy to prevent immune destruction leading to beta cell loss.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.